Latimer K M, Ruffin R E
Department of Medicine, Flinders Medical Center, Bedford Park, South Australia.
Eur J Clin Pharmacol. 1990;39(5):441-5. doi: 10.1007/BF00280933.
Responsiveness to inhaled histamine and DL propranolol hydrochloride was measured in 31 adult asthmatics and compared with bronchoconstriction provoked by acute oral propranolol dosing (max 160 mg). Twelve asthmatics developed greater than or equal to 15% reduction in the forced expired volume in 1 s (FEV1), 2 h after less than or equal to 100 mg oral propranolol; cardiac beta-adrenoceptor blockade was confirmed by cycle exercise tests in the 19 without airway response. The provocative inhaled dose of each aerosol causing a 20% fall in FEV1 (PC20) was lower, histamine 0.43 mg.ml-1, propranolol 3.12 mg.ml-1, in the 12 with a positive oral test compared with the 19 with a negative test, PC20 histamine 1.65 mg.ml-1, PC20 propranolol 16.2 mg.ml-1 (P less than 0.001 for both aerosols). A correlation was demonstrated between the PC20 values for asthmatics with a negative oral test (r = 0.72, P less than 0.001, n = 19) but not for the remainder (r = 0.14, P greater than 0.05, n = 12). Plasma propranolol concentrations (CL, ng.ml-1) after the final oral dose did not correlate with the % delta FEV1 (26.3) (r = -0.28) when an airway response was provoked or with the reduction in exercise tachycardia (25.9%) (r = 0.31) when no bronchoconstriction occurred. CL exceeded the limit of detection after the final inhaled propranolol dose (7.5 ng.ml-1) and was weakly related to the PC20 propranolol value (r = 0.53, P = 0.01, n = 27). The prevalence of a positive oral challenge was low in this group (39%).(ABSTRACT TRUNCATED AT 250 WORDS)
对31名成年哮喘患者测量了对吸入组胺和盐酸普萘洛尔的反应性,并与急性口服普萘洛尔(最大剂量160毫克)引起的支气管收缩进行了比较。12名哮喘患者在口服普萘洛尔剂量小于或等于100毫克后2小时,1秒用力呼气量(FEV1)下降大于或等于15%;在19名无气道反应的患者中,通过循环运动试验证实了心脏β-肾上腺素能受体阻滞。与19名口服试验阴性的患者相比,12名口服试验阳性的患者中,导致FEV1下降20%(PC20)的每种气雾剂的激发吸入剂量较低,组胺为0.43毫克/毫升,普萘洛尔为3.12毫克/毫升,PC20组胺为1.65毫克/毫升,PC20普萘洛尔为16.2毫克/毫升(两种气雾剂P均小于0.001)。口服试验阴性的哮喘患者的PC20值之间存在相关性(r = 0.72,P小于0.001,n = 19),但其余患者不存在相关性(r = 0.14,P大于0.05,n = 12)。最终口服剂量后的血浆普萘洛尔浓度(CL,纳克/毫升)与激发气道反应时的%ΔFEV1(26.3)(r = -0.28)或未发生支气管收缩时运动性心动过速的降低(25.9%)(r = 0.31)均无相关性。最终吸入普萘洛尔剂量(7.5纳克/毫升)后CL超过检测限,且与普萘洛尔的PC20值弱相关(r = 0.53,P = 0.01,n = 27)。该组口服激发试验阳性的发生率较低(39%)。(摘要截取自250字)